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Amyloidosis of the urinary bladder is a rare cause of gross hematuria. In patients with systemic amyloidosis,
identification is nearly always related to cardiac complaints; urologic presenting symptoms are extremely un
common. We present a 77-year-old male patient with painless gross hematuria ultimately found to be secondary
to systemic wild-type transthyretin amyloidosis. He underwent transurethral resection of the bladder lesion and
was initiated on transthyretin stabilizing medication. In the 6 months since starting treatment, the patient has
had no further episodes of gross hematuria, but will require cystoscopic surveillance for evidence of recurrence
or concomittment urothelial carcinoma.

1. Introduction
Amyloidosis is a disease characterized by the misfolding of proteins
and extracellular deposition of insoluble fibrils in various tissues. The
deposition site of these proteins is variable and accounts for the het
erogeneous symptomatology. More than 30 distinct misfolded proteins
have been identified, the most common of which are transthyretin
(ATTR) and light-chain (AL) amyloid.1 Amyloid deposition can occur
locally, impacting one discrete organ, or systemically, with the latter
associated with poorer prognosis and more severe quality of life impacts.
It is known that the bladder can be involved in systemic ATTR
amyloidosis, though the incidence of this phenomenon is unknown. It is
exceedingly rare and there is a scarcity of literature in which urologic
symptoms prompt a work-up and eventual diagnosis of systemic ATTR
amyloidosis. No guidelines regarding management and follow-up of
bladder amyloidosis exist.
Described here is a patient presenting with gross hematuria who was
found to have systemic ATTR amyloidosis.
2. Case presentation
A 77-year-old male with past medical history of chronic myeloge
nous leukemia (CML) stable on imatinib, dilated cardiomyopathy
thought to be related to previous nilotinib treatment, carpal tunnel
syndrome, lumbar stenosis and no tobacco history presented to the

emergency department with gross hematuria. His urine showed large
blood and was negative for leukocyte esterase and nitrites. His hemo
globin was 12.0, stable from prior, and his coagulation labs were
normal. Non-contrast CT scan of the abdomen and pelvis revealed
bilateral non-obstructing lower pole stones with no evidence of hydro
nephrosis and a mildly thickened bladder wall, which was attributed to
prostatic hypertrophy.
The patient reported to the outpatient urology clinic, where office
cystoscopy showed a questionable lesion with adherent clot on the
posterior wall of the bladder as well as adjacent cobblestoned mucosa
and diffuse trabeculations. Urine cytology was negative for malignancy.
The patient underwent a transurethral resection of bladder tumor during
which a resectoscope was introduced and the lesion was widely excised
with adequate hemostasis. Pathology report showed acellular, eosino
philic deposits in the lamina propria (Fig. 1). Congo red stain was pos
itive and demonstrated apple green birefringence under polarized light
(Fig. 2), suggestive of a diagnosis of amyloid. The sample was sent for
liquid chromatography tandem mass spectrometry (LC MS/MS) which
revealed peptide sequences consistent with ATTR amyloid. Genetic
testing did not show any mutations in ATTR proteins, suggestive of wildtype amyloidosis.
Plasma cell dyscrasias were ruled out biochemically, including
normal urine protein electrophoresis (UPEP), serum protein electro
phoresis (SPEP) and free serum light chains. No evidence of gastroin
testinal, liver or kidney involvement was found. In light of the patient’s
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Fig. 1. H&E stain at 100× magnification. Acellular, amorphous eosinophilic material in the lamina propria underlying benign urothelium.

Fig. 2. Congo Red stain at 200× magnification. Acellular, amorphous material staining red orange with apple-green birefringence under polarized light. (For
interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

history of dilated cardiomyopathy, the patient underwent additional
workup, which revealed characteristic findings of cardiac amyloid
deposition including cardiac magnetic resonance imaging (MRI) with
circumferential left ventricular hypertrophy, patchy late gadolinium
enhancement and failure of the myocardium to null on Look-Locker
sequences, as well as cardiac pyrophosphate (PYP) scan with diffuse,
3+ uptake of technetium pyrophosphate.
The patient was initiated on tafamidis therapy for his systemic, wildtype ATTR amyloidosis. In the 6 months since starting treatment, there
have been no further episodes of gross hematuria or evidence of wors
ening left ventricular dysfunction which would indicate additional
amyloid deposition.

largest case series which highlighted 31 patients with primary localized
AL amyloidosis of the urinary tract.2 Of the patients in the series, 84%
were treated with simple resection or fulguration. Localized amyloidosis
of the bladder is almost exclusively due to AL amyloid, which is likely
related to chronic inflammation and recruitment of monoclonal plasma
cells.
Systemic ATTR amyloid may also deposit in the urinary tract, as was
seen in the patient presented above. Typical presentation of ATTR
amyloidosis includes cardiac symptoms such as palpitations, dyspnea on
exertion and edema, as well as noncardiac symptoms like carpal tunnel
and spinal stenosis.1 The pathogenesis of wild-type ATTR amyloidosis is
related to aging, in which the precursor proteins lose their ability to fold
properly over time.
At present time, there is only one case report documenting the
diagnosis of systemic ATTR amyloidosis following an episode of hema
turia,3 with the case above highlighting an additional patient. A high
degree of suspicion is necessary to diagnose amyloidosis, as there are
many more common causes of hematuria. Early diagnosis and initiation
of treatment can reduce continued amyloid deposition, significantly
improving all-cause mortality.1 ATTR amyloid deposition can also cause
other urologic complaints, with as many as 83% of patients with

3. Discussion
Amyloidosis involving the kidneys, ureters, prostate or bladder is
incredibly rare. Amyloid lesions in the bladder mimic urothelial carci
noma, both in appearance and presentation, having been described as
polypoid, ulcerated and hemorrhagic papules which are found after
episodes of painless gross hematuria. Amyloidosis localized to the uri
nary bladder has been described in less than 200 cases, including the
2
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systemic disease reporting LUTS, greater than 40% reporting sexual
dysfunction and a third reporting UI,4 which are thought to be the result
of peripheral and autonomic nerve involvement. While it is important to
acknowledge that the aging population in general has a high prevalence
of these urologic complaints, any suspicion of a secondary cause of a
patient’s symptoms should not be ignored.
The recurrence rate of bladder amyloidosis is reported to be 54%,2
indicating the importance of continued urologic monitoring in these
patients. More formidable than amyloid recurrence is the association
between bladder amyloid and urothelial carcinoma. In a retrospective
review, the rate of urothelial carcinoma in patients with known bladder
amyloid was 48%, a third of which were high-grade at the time of
diagnosis.5 Histologically, amyloid deposits were seen adjacent to the
malignant lesions, never seen within the tumor itself. Surveillance
cystoscopy in patients with bladder amyloidosis is therefore recom
mended to identify local recurrence and possible urothelial carcinomas.
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